18alpha-Glycyrrhetinic acidCAS# 1449-05-4 |
- Glycyrrhetinic acid
Catalog No.:BCN5942
CAS No.:471-53-4
- Liquiritic acid
Catalog No.:BCN8332
CAS No.:10379-72-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1449-05-4 | SDF | Download SDF |
PubChem ID | 3230 | Appearance | White powder |
Formula | C30H46O4 | M.Wt | 470.7 |
Type of Compound | Isoprenoids | Storage | Desiccate at -20°C |
Synonyms | 18α-Glycyrrhetic acid; 18-Isoglycyrrhetinic acid | ||
Solubility | Soluble in ethanol; practically insoluble in water | ||
Chemical Name | 10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid | ||
SMILES | CC1(C2CCC3(C(C2(CCC1O)C)C(=O)C=C4C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C | ||
Standard InChIKey | MPDGHEJMBKOTSU-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
18alpha-Glycyrrhetinic acid Dilution Calculator
18alpha-Glycyrrhetinic acid Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1245 mL | 10.6225 mL | 21.245 mL | 42.4899 mL | 53.1124 mL |
5 mM | 0.4249 mL | 2.1245 mL | 4.249 mL | 8.498 mL | 10.6225 mL |
10 mM | 0.2124 mL | 1.0622 mL | 2.1245 mL | 4.249 mL | 5.3112 mL |
50 mM | 0.0425 mL | 0.2124 mL | 0.4249 mL | 0.8498 mL | 1.0622 mL |
100 mM | 0.0212 mL | 0.1062 mL | 0.2124 mL | 0.4249 mL | 0.5311 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 1-Methyl-aminomethyl naphthalene
Catalog No.:BCC8471
CAS No.:14489-75-9
- ML314
Catalog No.:BCC4154
CAS No.:1448895-09-7
- MRS 2693 trisodium salt
Catalog No.:BCC7386
CAS No.:1448858-83-0
- 4',9,9'-Trihydroxy-3'-methoxy-3,7'-epoxy-4,8'-oxyneolignan
Catalog No.:BCN1563
CAS No.:144881-21-0
- Junipediol B
Catalog No.:BCN6252
CAS No.:144881-19-6
- Resiquimod (R-848)
Catalog No.:BCC4073
CAS No.:144875-48-9
- Garjasmin
Catalog No.:BCN6251
CAS No.:144868-43-9
- Alpiniaterpene A
Catalog No.:BCN7085
CAS No.:1448667-05-7
- Deflazacort
Catalog No.:BCC8928
CAS No.:14484-47-0
- 5-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
Catalog No.:BCC8720
CAS No.:144809-28-9
- L-703,664 succinate
Catalog No.:BCC7437
CAS No.:144776-01-2
- Brachynoside heptaacetate
Catalog No.:BCN6249
CAS No.:144765-80-0
- 21-Episerratenediol
Catalog No.:BCN6253
CAS No.:1449-06-5
- 24-Methylenecycloartanone
Catalog No.:BCN7244
CAS No.:1449-08-7
- 24-Methylenecycloartan-3-ol
Catalog No.:BCN6254
CAS No.:1449-09-8
- Androst-5-en-3-ol-7,17-dione acetate
Catalog No.:BCC8822
CAS No.:1449-61-2
- Senexin B
Catalog No.:BCC3990
CAS No.:1449228-40-3
- K145 hydrochloride
Catalog No.:BCC4072
CAS No.:1449240-68-9
- Chlojaponilactone B
Catalog No.:BCN7400
CAS No.:1449382-91-5
- Boeravinone O
Catalog No.:BCN6693
CAS No.:1449384-21-7
- DDR1-IN-1
Catalog No.:BCC5170
CAS No.:1449685-96-4
- DGAT1-IN-1
Catalog No.:BCC5511
CAS No.:1449779-49-0
- Pregnenolone
Catalog No.:BCN6255
CAS No.:145-13-1
- ω-Agatoxin IVA
Catalog No.:BCC7488
CAS No.:145017-83-0
Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects.[Pubmed:30880980]
Int J Nanomedicine. 2019 Mar 8;14:1789-1804.
Background: Recent efforts have been focused on combining two or more therapeutic approaches with different mechanisms to enhance antitumor therapy. Moreover, nanosize drug-delivery systems for codelivering two drugs with proapoptotic and antiangiogenic activities have exhibited great potential in efficient treatment of cancers. Methods: Glycyrrhetinic acid (GA)-modified liposomes (GA LPs) for liver-targeted codelivery of curcumin (Cur) and combretastatin A4 phosphate (CA4P) were prepared and characterized. In vitro cellular uptake, cytotoxicity, cell migration, in vivo biodistribution, antitumor activity, and histopathological studies were performed. Results: Compared with unmodified LPs (Cur-CA4P LPs), Cur-CA4P/GA LPs were taken up effectively by human hepatocellular carcinoma cells (BEL-7402) and showed higher cytotoxicity than free drugs. In vivo real-time near-infrared fluorescence-imaging results indicated that GA-targeted LPs increased accumulation in the tumor region. Moreover, Cur-CA4P/GA LPs showed stronger inhibition of tumor proliferation than Cur, Cur + CA4P, and Cur-CA4P LPs in vivo antitumor studies, which was also verified by H&E staining. Conclusion: GA-modified LPs can serve as a promising nanocarrier for liver-targeted co-delivery of antitumor drugs against hepatocellular carcinoma.
Glycyrrhetinic Acid Improves Insulin-Response Pathway by Regulating the Balance between the Ras/MAPK and PI3K/Akt Pathways.[Pubmed:30871060]
Nutrients. 2019 Mar 12;11(3). pii: nu11030604.
Glycyrrhetinic acid (GA), a bioactive component in the human diet, has been reported to improve hyperglycemia, dyslipidemia, insulin resistance and obesity in rats with metabolic syndrome. However, GA-specific target proteins and the mechanisms involved in the downstream signaling and cross-talk to improve insulin sensitivity have not been fully elucidated. In this study, the potential targets of GA were identified by chemical proteomics strategies using serial GA probes for target fishing and cell molecular imaging. Intracellular enzyme activity evaluation and insulin resistance models were used for validating the function of the target proteins on the downstream insulin signaling pathways. Collectively, our data demonstrate that GA improved the insulin-responsive pathway and glucose consumption levels via multiple diabetogenic factors that activated the insulin signaling pathway in HepG2 cells. GA improved Glucose transporter 4(GLUT4) expression by targeting the Ras protein to regulate the mitogen-activated protein kinase (MAPK) pathway. GA exhibited a strong inhibitory effect on IRS1ser307 phosphorylation in cells treated with the Protein kinase C (PKC) activator Phorbol 12-myristate 13-acetate (PMA.) Consistently, IRS1ser307 phosphorylation was also inhibited by GA in Free fatty acid (FFA)-treated HepG2 cells. GA also inhibited the PMA-induced phosphorylation of IkappaB kinase alpha/beta (IKKalpha/beta), c-Jun N-terminal kinase (JNK) and p38 proteins (P38), suggesting that IKKalpha/beta, JNK and P38 activation is dependent on PKC activity.
Synthesis and structure-activity relationship studies of water-soluble beta-cyclodextrin-glycyrrhetinic acid conjugates as potential anti-influenza virus agents.[Pubmed:30731401]
Eur J Med Chem. 2019 Mar 15;166:328-338.
Glycyrrhetinic acid (GA) is a major constituent of the herb Glycyrrhiza glabra, and many of its derivatives demonstrate a broad spectrum of antiviral activities. In the current study, 18 water-soluble beta-cyclodextrin (CD)-GA conjugates, in which GA was covalently coupled to the primary face of beta-CD using 1,2,3-triazole moiety along with varying lengths of linker, were synthesized via copper-catalyzed azide-alkyl cycloaddition reaction. Benefited from the attached beta-CD moiety, all these conjugates showed lower hydrophobicity (AlogP) compared with their parent compound GA. With the exception of per-O-methylated beta-CD-GA conjugate (35), all other conjugates showed no significant cytotoxicity to MDCK cells, and these conjugates were then screened against A/WSN/33 (H1N1) virus using the cytopathic effect assay. The preliminary results indicated that six conjugates showed promising antiviral activity, and the C-3 and C-30 of GA could tolerate some modifications. Our findings suggested that GA could be used as a lead compound for the development of potential anti-influenza virus agents.
Protective Effects of 18beta-Glycyrrhetinic Acid on Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats.[Pubmed:30723409]
Front Pharmacol. 2019 Jan 22;10:13.
Pulmonary arterial hypertension (PAH) is a destructive and rare disorder characterized by a progressive increase in pulmonary artery pressure and vasoconstriction, ultimately leading to right ventricular failure and death. 18beta-Glycyrrhetinic acid (18beta-GA) is an active ingredient in the commonly used Chinese herbal medicine radix glycyrrhizae, and it possesses antioxidant, anti-inflammatory, anti-tumor, and other pharmacological properties. This study aimed to determine whether 18beta-GA has protective effects against monocrotaline (MCT)-induced PAH and whether it is associated with oxidative stress. The PAH of rats was induced by MCT (60 mg/kg) and oral administration of 18beta-GA (100, 50, or 25 mg/kg/day), sildenafil (30 mg/kg), or saline for 21 consecutive days. The development of PAH was evaluated by hemodynamic parameters and right ventricular hypertrophy index. Hematoxylin and eosin staining, Masson trichrome staining, and electron microscopy were used to determine the degree of vascular remodeling and proliferation in lung tissue. Moreover, the antioxidant capacity and malondialdehyde levels in the lungs were measured according to the instructions provided by the test kits, and the expression levels of nicotinamide adenine dinucleotide phosphate oxidase-2 (Nox2) and Nox4 were detected through Western blot analysis. Results of our study indicated that 18beta-GA treatment significantly improved the hemodynamic and pathomorphological data of the rats, reduced the changes in oxidative stress biomarkers, and inhibited Nox2 and Nox4 expression. Our research indicated that 18beta-GA has a protective effect against MCT-induced PAH by inhibiting oxidative stress in rats.
Liver-Targeted Combination Therapy Basing on Glycyrrhizic Acid-Modified DSPE-PEG-PEI Nanoparticles for Co-delivery of Doxorubicin and Bcl-2 siRNA.[Pubmed:30723405]
Front Pharmacol. 2019 Jan 22;10:4.
Combination therapy based on nano-sized drug delivery system has been developed as a promising strategy by combining two or more anti-tumor mechanisms. Here, we prepared liver-targeted nanoparticles (GH-DPP) composed of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol-polyetherimide (DSPE-PEG-PEI) with Glycyrrhetinic acid-modified hyaluronic acid (GA-HA) for co-delivery of doxorubicin (DOX) and Bcl-2 siRNA. Particles size, zeta potential and morphology were determined for the drug-loaded GH-DPP nanoparticles (siRNA/DOX/GH-DPP). Cellular uptake and in vitro cytotoxicity were analyzed against HepG2 cells. In vivo bio-distribution and anti-tumor therapeutic effects of siRNA/DOX/GH-DPP were evaluated in H22-bearing mice. The results showed that siRNA/DOX/GH-DPP nanoparticles were nearly spherical and showed dose-dependent cytotoxicity against HepG2 cells. Compared to Glycyrrhetinic acid-free co-delivery system (siRNA/DOX/DPP) and GH-DPP nanoparticles for delivery of DOX or Bcl-2 siRNA alone, siRNA/DOX/GH-DPP nanoparticles could induce more cellular apoptosis, and showed higher anti-tumor effect. Herein GH-DPP nanoparticles could simultaneously deliver both chemotherapy drugs and siRNA into the tumor region, exhibiting great potential in anti-tumor therapy.